• Next-Generation Pharmacist Awards Gala
  • Mylan Launches Generic Precedex Sedative as Hospira Sues FDA
  • Fall Allergies: The Pharmacist’s Role in Allergic Rhinitis Symptom Management and Patient Counseling
  • Statins After ACS: Continue Therapy for at Least 5 Years
  • Self-Care for Pain Awareness

Breaking News

Relief Group Calls Ebola Response Inadequate While American Patients Get Tested for Possible Exposure
Doctors Without Borders says virus cannot be contained without massive mobilization of resources to West Africa.
Amgen’s investigational treatment for secondary hyperparathyroidism in patients with chronic kidney disease who are receiving hemodialysis achieved its primary and secondary endpoints in a second Phase 3 study.
Key points from the Infectious Diseases Society of America’s updated guidelines for vaccination of immunocompromised individuals.
The viral Ice Bucket Challenge and the first effort to estimate the prevalence of amyotrophic lateral sclerosis have raised awareness of the neurodegenerative disease.
The FDA has granted approval to Genzyme’s eliglustat (Cerdelga), the only first-line oral therapy for patients with Type 1 Gaucher disease.
A new drug was recently given tentative approval by the FDA to help patients with both type 1 and type 2 diabetes.
Patients continue to benefit from high-dose atorvastatin therapy for at least 5 years after acute coronary syndrome, according to a new study.

From the Issue

Previous TabNext Tab
Strategic Alliance Partners
Latest Issues